Usefulness of 3-month protocol biopsy of kidney allograft to detect subclinical rejection under triple immunosuppression with basiliximab

A single center experience

Kosuke Masutani, Hidehisa Kitada, akihiro tsuchimoto, Shunsuke Yamada, Hideko Noguchi, Kazuhiko Tsuruya, Masao Tanaka, Mitsuo Iida

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Theoretically, an early protocol biopsy (PB) serves to detect subclinical rejection (SCR), allowing early treatment and prevention of acute rejection (AR) and chronic graft injuries. In this retrospective study, we investigated the incidence of biopsy-proven AR (BPAR) and the usefulness of a 3-month PB in detecting SCR in kidney transplant (KT) and simultaneous pancreas-kidney transplant (SPKT) recipients who received triple immunosuppression and basiliximab. Methods: Between January 2007 and September 2009, 116 patients received transplantation (KT = 112, SPKT = 4). In August 2008, we changed our PB policy and started to collect PB after 3 months instead of a pre-discharge biopsy performed 1 month after transplantation. Here we compare the incidence of SCR (defined as Banff grade Ia or higher) between the pre-discharge PB group and the 3-month PB group. PB was obtained from 41 patients before discharge (pre-discharge PB group), and from 49 patients 3 months after transplantation (3-month PB group). Results: Among all recipients, 21 patients were diagnosed with BPAR (estimated incidence of BPAR 20.1%); including 13 (62.0%) diagnosed from 31 to 180 postoperative days (POD), and only 3 (14.3%) within 30 POD. The incidence of BPAR was not different between the two groups (19.5 and 20.8%, respectively); however, 4 of 8 recipients in the 3-month PB group were diagnosed with SCR, compared to none in the pre-discharge PB group (P<0.05). Conclusion: Since the use of triple immunosuppression and basiliximab delayed the onset of AR, we recommend that in order to detect SCR, PB should be obtained 3 months postoperatively.

Original languageEnglish
Pages (from-to)264-268
Number of pages5
JournalClinical and Experimental Nephrology
Volume15
Issue number2
DOIs
Publication statusPublished - Apr 1 2011

Fingerprint

Immunosuppression
Allografts
Kidney
Biopsy
basiliximab
Incidence
Transplants
Pancreas
Transplantation
Patient Discharge
Graft Rejection
Kidney Transplantation

All Science Journal Classification (ASJC) codes

  • Physiology
  • Nephrology
  • Physiology (medical)

Cite this

Usefulness of 3-month protocol biopsy of kidney allograft to detect subclinical rejection under triple immunosuppression with basiliximab : A single center experience. / Masutani, Kosuke; Kitada, Hidehisa; tsuchimoto, akihiro; Yamada, Shunsuke; Noguchi, Hideko; Tsuruya, Kazuhiko; Tanaka, Masao; Iida, Mitsuo.

In: Clinical and Experimental Nephrology, Vol. 15, No. 2, 01.04.2011, p. 264-268.

Research output: Contribution to journalArticle

@article{71c46150b9f54254a2cb3774b5b453ba,
title = "Usefulness of 3-month protocol biopsy of kidney allograft to detect subclinical rejection under triple immunosuppression with basiliximab: A single center experience",
abstract = "Background: Theoretically, an early protocol biopsy (PB) serves to detect subclinical rejection (SCR), allowing early treatment and prevention of acute rejection (AR) and chronic graft injuries. In this retrospective study, we investigated the incidence of biopsy-proven AR (BPAR) and the usefulness of a 3-month PB in detecting SCR in kidney transplant (KT) and simultaneous pancreas-kidney transplant (SPKT) recipients who received triple immunosuppression and basiliximab. Methods: Between January 2007 and September 2009, 116 patients received transplantation (KT = 112, SPKT = 4). In August 2008, we changed our PB policy and started to collect PB after 3 months instead of a pre-discharge biopsy performed 1 month after transplantation. Here we compare the incidence of SCR (defined as Banff grade Ia or higher) between the pre-discharge PB group and the 3-month PB group. PB was obtained from 41 patients before discharge (pre-discharge PB group), and from 49 patients 3 months after transplantation (3-month PB group). Results: Among all recipients, 21 patients were diagnosed with BPAR (estimated incidence of BPAR 20.1{\%}); including 13 (62.0{\%}) diagnosed from 31 to 180 postoperative days (POD), and only 3 (14.3{\%}) within 30 POD. The incidence of BPAR was not different between the two groups (19.5 and 20.8{\%}, respectively); however, 4 of 8 recipients in the 3-month PB group were diagnosed with SCR, compared to none in the pre-discharge PB group (P<0.05). Conclusion: Since the use of triple immunosuppression and basiliximab delayed the onset of AR, we recommend that in order to detect SCR, PB should be obtained 3 months postoperatively.",
author = "Kosuke Masutani and Hidehisa Kitada and akihiro tsuchimoto and Shunsuke Yamada and Hideko Noguchi and Kazuhiko Tsuruya and Masao Tanaka and Mitsuo Iida",
year = "2011",
month = "4",
day = "1",
doi = "10.1007/s10157-010-0385-x",
language = "English",
volume = "15",
pages = "264--268",
journal = "Clinical and Experimental Nephrology",
issn = "1342-1751",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Usefulness of 3-month protocol biopsy of kidney allograft to detect subclinical rejection under triple immunosuppression with basiliximab

T2 - A single center experience

AU - Masutani, Kosuke

AU - Kitada, Hidehisa

AU - tsuchimoto, akihiro

AU - Yamada, Shunsuke

AU - Noguchi, Hideko

AU - Tsuruya, Kazuhiko

AU - Tanaka, Masao

AU - Iida, Mitsuo

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Background: Theoretically, an early protocol biopsy (PB) serves to detect subclinical rejection (SCR), allowing early treatment and prevention of acute rejection (AR) and chronic graft injuries. In this retrospective study, we investigated the incidence of biopsy-proven AR (BPAR) and the usefulness of a 3-month PB in detecting SCR in kidney transplant (KT) and simultaneous pancreas-kidney transplant (SPKT) recipients who received triple immunosuppression and basiliximab. Methods: Between January 2007 and September 2009, 116 patients received transplantation (KT = 112, SPKT = 4). In August 2008, we changed our PB policy and started to collect PB after 3 months instead of a pre-discharge biopsy performed 1 month after transplantation. Here we compare the incidence of SCR (defined as Banff grade Ia or higher) between the pre-discharge PB group and the 3-month PB group. PB was obtained from 41 patients before discharge (pre-discharge PB group), and from 49 patients 3 months after transplantation (3-month PB group). Results: Among all recipients, 21 patients were diagnosed with BPAR (estimated incidence of BPAR 20.1%); including 13 (62.0%) diagnosed from 31 to 180 postoperative days (POD), and only 3 (14.3%) within 30 POD. The incidence of BPAR was not different between the two groups (19.5 and 20.8%, respectively); however, 4 of 8 recipients in the 3-month PB group were diagnosed with SCR, compared to none in the pre-discharge PB group (P<0.05). Conclusion: Since the use of triple immunosuppression and basiliximab delayed the onset of AR, we recommend that in order to detect SCR, PB should be obtained 3 months postoperatively.

AB - Background: Theoretically, an early protocol biopsy (PB) serves to detect subclinical rejection (SCR), allowing early treatment and prevention of acute rejection (AR) and chronic graft injuries. In this retrospective study, we investigated the incidence of biopsy-proven AR (BPAR) and the usefulness of a 3-month PB in detecting SCR in kidney transplant (KT) and simultaneous pancreas-kidney transplant (SPKT) recipients who received triple immunosuppression and basiliximab. Methods: Between January 2007 and September 2009, 116 patients received transplantation (KT = 112, SPKT = 4). In August 2008, we changed our PB policy and started to collect PB after 3 months instead of a pre-discharge biopsy performed 1 month after transplantation. Here we compare the incidence of SCR (defined as Banff grade Ia or higher) between the pre-discharge PB group and the 3-month PB group. PB was obtained from 41 patients before discharge (pre-discharge PB group), and from 49 patients 3 months after transplantation (3-month PB group). Results: Among all recipients, 21 patients were diagnosed with BPAR (estimated incidence of BPAR 20.1%); including 13 (62.0%) diagnosed from 31 to 180 postoperative days (POD), and only 3 (14.3%) within 30 POD. The incidence of BPAR was not different between the two groups (19.5 and 20.8%, respectively); however, 4 of 8 recipients in the 3-month PB group were diagnosed with SCR, compared to none in the pre-discharge PB group (P<0.05). Conclusion: Since the use of triple immunosuppression and basiliximab delayed the onset of AR, we recommend that in order to detect SCR, PB should be obtained 3 months postoperatively.

UR - http://www.scopus.com/inward/record.url?scp=79959272340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959272340&partnerID=8YFLogxK

U2 - 10.1007/s10157-010-0385-x

DO - 10.1007/s10157-010-0385-x

M3 - Article

VL - 15

SP - 264

EP - 268

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

SN - 1342-1751

IS - 2

ER -